This study focuses on individuals with a Hepatic tumor, which is a growth or mass found in the liver. The research aims to determine if a specific imaging method can better predict potential health problems following surgery to remove these tumors. During the study, a substance called technetium (99mtc) galactosyl serum albumin is administered through an intravenous administration, which means it is delivered directly into a vein. This substance is used in combination with SPECT/CT, a specialized imaging technique that combines different types of scans to create detailed pictures of the body.

The process involves comparing the results of the new imaging method with standard ways of checking how well the liver is working. These existing methods include the indocyanine green clearance test, which measures how the liver processes a specific dye, and various scoring systems like the Child-Pugh score and the MELD score used to assess liver health. Additionally, ultrasound elastography, a non-invasive way to check the stiffness of the liver, may be used. By comparing these different tools, the study seeks to find the most accurate way to identify patients who might face complications after their surgery.